Value AD
CAN BE
ALTERNATIVE
INVESTMENT
Tuberculosis Elimination and Laboratory Cooperative Agreement
CDC-RFA-PS-25-0003
Centers for Disease Control - NCHHSTP
Funding Opportunity Number: CDC-RFA-PS-25-0003
Opportunity Category: Discretionary
Expected Number of Awards: 57
CFDA Number(s): 93.116 -- Project Grants and Cooperative Agreements for Tuberculosis Control Programs
Cost Sharing or Matching Requirement: No
Posted Date: Jul 01, 2024 12:00:00 AM EDT
Closing Date: Sep 09, 2024 12:00:00 AM EDT
Closing Date Details: Electronically submitted applications must be submitted no later than 11:59 pm ET on the listed application due date.
Estimated Total Program Funding: 374456055
Eligible Applicants: State governments,City or township governments,Others (see text field entitled "Additional Information on Eligibility" for clarification),Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility",County governments
Additional Information on Eligibility: Government Organizations:Territorial governments or their bona fide agents in the Commonwealth of Puerto Rico, and the Virgin Islands. Non-government Organizations: Other:In accordance with the statutory authority provided in Section 317E(d) of the PHS Act (42 USC 247b-6(d)):The applicant must provide evidence that they have the necessary public health infrastructure and authority to conduct TB disease surveillance; report TB surveillance data to CDC; respond to TB outbreaks; contain emerging TB disease threats; conduct TB disease investigation, intervention, and follow-up and perform TB laboratory testing for the eligible project area for which funding is sought. The applicant must upload two attachments in the application entitled Attachment A- “TB Prevention and Control Elimination Plan” and Attachment B- “Evidence of Jurisdiction Infrastructure” that includes the following two documents:TB Prevention, Control and Elimination Plan--A plan regarding the prevention, control, and elimination of tuberculosis in the geographic area with respect to which the grant is sought. Summary of a plan, including laboratory activities, must be included.Evidence of Jurisdiction Infrastructure-Summary of jurisdiction’s ability to conduct TB disease surveillance, report surveillance data to CDC, respond to outbreaks, contain emerging disease threats, conduct disease investigation, intervention, and follow-up as well as those performing laboratory testing.Required documents must be uploaded as Attachment A and Attachment B under Appendix A. Failure to upload the required documents would deem the applicant non-responsive.The applicant cannot request an award greater than the anticipated budget formula for the project area.
Agency Name: Centers for Disease Control - NCHHSTP
Description: CDC announces available Fiscal Year (FY) 2025 funds to complement tuberculosis (TB) prevention and control activities and laboratory services at state and local levels to reduce TB morbidity and mortality. The goal of this funding is to prevent transmission of M. tuberculosis (TB) and prevent progression from latent TB infection to active TB disease. Funding levels are determined by formulas reflecting TB disease incidence, case complexity, program performance, and laboratory workload data. Strategies and activities include diagnosis/treatment of persons with TB disease and persons with latent TB infection (LTBI); examination of immigrants and refugees who have an overseas B classification for TB; targeted testing for, and treatment of, LTBI; program planning, evaluation, and improvement; epidemiologic surveillance and response; human resource development and partnership activities; and public health laboratory strengthening. Expected outcomes include (but are not limited to) decreases in TB incidence; increases in patients completing treatment within 12 months; increases in HIV and drug susceptibility testing in TB cases; increases in LTBI testing and treatment completion rates of those recommended for treatment; increases in accuracy and completeness of surveillance, genotyping, and whole-genome sequencing data; improvement in turnaround times for specimen receipt and laboratory testing and implementation of TB elimination plans.
Grantor Contact Information: Martha Boisseau mboisseau@cdc.gov
